Minimal Residual Disease as a Biological Trait: Rethinking Disease Persistence in Hematologic Malignancies
European Journal of Haematology · 2026-08 · 117 (2) · 320-337
DOI: 10.1111/ejh.70203 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift European Journal of Haematology, online erschienen am 26.04.2026. Verfasst von Santino Caserta und 14 weiteren Autor:innen. Beteiligte Einrichtung: Hematology Unit, Department of Onco-Hematology, AO of Cosenza, Cosenza, Italy. Hauptthemen laut MEDLINE: Neoplasm, Residual, Hematologic Neoplasms. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 77 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Minimal residual disease (MRD) has emerged as a central biomarker in hematologic malignancies, enabling highly sensitive detection of tumor persistence beyond conventional morphologic assessment and serving as an increasingly important surrogate endpoint in clinical trials. Despite these advances, MRD remains predominantly conceptualized as a quantitative variable reflecting residual tumor burden below assay detection thresholds. While this paradigm has enabled standardization of response criteria and cross‐trial comparisons, it does not fully explain key clinical observations, including heterogeneous outcomes among MRD‐positive patients, durable remissions despite detectable disease, and discordance between molecular and imaging‐based assessments. Here, we propose a conceptual framework in which MRD is redefined as a biologically determined trait—a functional phenotype of persistence—rather than a purely quantitative state. We review the mechanisms that shape this phenotype, including therapy‐driven clonal selection, epigenetic and transcriptional plasticity, metabolic adaptation, immune evasion, and microenvironmental niche protection. These processes collectively define the functional fitness of residual tumor cells and their capacity to survive therapeutic pressure, remain dormant, and ultimately drive relapse. This framework provides a mechanistic explanation for clinically observed phenomena—including molecular–imaging discordance and variable relapse kinetics—arguing that these are not merely technical artifacts but reflect distinct, partially independent biological dimensions of residual disease. We further outline a multidimensional model of MRD integrating molecular, spatial, immune, metabolic, and functional dimensions. Operationally, we define MRD as a biological trait across five interacting axes: (i) clonal fitness, (ii) phenotypic plasticity, (iii) metabolic adaptability, (iv) immune evasion, and (v) microenvironmental dependence. Conceptualizing MRD as a dynamic biological trait offers a more comprehensive and testable model of disease persistence and supports the development of mechanism‐based MRD‐directed therapeutic strategies in hematologic malignancies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Hematology Unit, Department of Onco-Hematology, AO of Cosenza, Cosenza, Italy.
- Emergency and Internal Medicine Department, Saint Joseph Hospital, East Jerusalem, Palestine.
- Department of Experimental and Clinical Medicine, University of Catanzaro, Catanzaro, Italy.
- Istituto di Fisiologia Clinica del CNR di Reggio Calabria, Consiglio Nazionale Delle Ricerche, Reggio Calabria, Italy.
- AIL Sezione di Cosenza, Cosenza, Italy.
- Department of Pharmacy, Health and Nutritional Science, University of Calabria, Rende, Italy.
ORCID-Profile: Francesco Mendicino, Massimo Gentile
Zitieren
APA
Caserta, S., Martino, E. A., Vigna, E., Skafi, M., Bruzzese, A., Amodio, N., Lucia, E., D'Arrigo, G., Olivito, V., Labanca, C., Mendicino, F., Alvaro, M. E., Tripepi, G., Morabito, F., & Gentile, M. (2026). Minimal Residual Disease as a Biological Trait: Rethinking Disease Persistence in Hematologic Malignancies. European Journal of Haematology, 117(2), 320-337. https://doi.org/10.1111/ejh.70203
Vancouver
Caserta S, Martino EA, Vigna E, Skafi M, Bruzzese A, Amodio N, et al. Minimal Residual Disease as a Biological Trait: Rethinking Disease Persistence in Hematologic Malignancies. European Journal of Haematology. 2026;117(2):320-337. doi:10.1111/ejh.70203
BibTeX
@article{Caserta2026,
author = {Caserta, Santino and Martino, Enrica Antonia and Vigna, Ernesto and Skafi, Mamdouh and Bruzzese, Antonella and Amodio, Nicola and Lucia, Eugenio and D'Arrigo, Graziella and Olivito, Virginia and Labanca, Caterina and Mendicino, Francesco and Alvaro, Maria Eugenia and Tripepi, Giovanni and Morabito, Fortunato and Gentile, Massimo},
title = {Minimal Residual Disease as a Biological Trait: Rethinking Disease Persistence in Hematologic Malignancies},
journal = {European Journal of Haematology},
year = {2026},
volume = {117},
number = {2},
pages = {320--337},
doi = {10.1111/ejh.70203}
}
EUVIMED